Exagen reports $19.9 million in Q2 2026 revenue, a 16% year-over-year increase, as it nears profitability.
Exagen set a quarterly revenue record of $19.9 million in Q2 2026, marking a 16% year-over-year increase. The company also achieved milestones in AVISE test volume and trailing 12-month average selling price (ASP).
The revenue growth aligns with Exagen’s prior guidance and reflects strong performance in its diagnostic and pharma segments. The company expects to reach $72M-$75M in revenue for 2026, signaling progress toward profitability.
Management highlighted record-breaking metrics but did not disclose immediate market reactions or stock movements.